Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Critically Ill Patients
NCT06156059Phase 4Not yet recruiting
- Sponsor
- Hospital Clínico San Carlos
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of melatonin in septic shock, ischemic stroke, hemorrhagic stroke and 1 more (8 arms), sponsored by Hospital Clínico San Carlos. Primary endpoint: Mortality at 90 days. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
melatonin
03
Conditions
septic shockischemic strokehemorrhagic strokecardiac arrest (SCA)
Beyond the preview
Go deeper on NCT06156059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156059.